Daewoong's Nabota approved for sale in Saudi Arabia, Ukraine

The botox maker aims to sell its product in over 100 countries, including China, by year-end

Daewoong Pharmaceutical's botox product Nabota
Daewoong Pharmaceutical's botox product Nabota
Ji-Hyun Lee 1
2022-05-19 11:03:46 bluesky@hankyung.com
Bio & Pharma

South Korea’s Daewoong Pharmaceutical Co. has obtained approval for the sale of its botulinum toxin product, Nabota, in Saudi Arabia and Ukraine.

Saudi Arabia, one of the largest markets for botulinum toxin, more commonly known as botox, in the Middle East will serve as the Korean company’s base for aggressive marketing in the region, Daewoong said on Wednesday.

It said Ukraine, the largest pharmaceutical market in Eastern Europe, will serve as its bridgehead for further increasing its botox sales across Europe.

Daewoong's Nabota
Daewoong's Nabota

With the latest approval in Saudi Arabia and Ukraine, Daewoong will be exporting Nabota to 58 countries.

The company said it aims to sell its botox product in over 100 countries, including China, by the end of this year.

Daewoong first unveiled Nabota in Korea in 2014.

Write to Ji-Hyun Lee at bluesky@hankyung.com
In-Soo Nam edited this article.
#Daewoong Pharmaceutical #botox #Nabota

Medytox-Hugel dispute over botox strain intensifies with ITC probe

Medytox-Hugel dispute over botox strain intensifies with ITC probe

Hugel is Korea’s largest botox maker A legal dispute over a botox strain between South Korean pharmaceutical company Medytox Inc. and its crosstown rival Hugel Inc. has intensified with the International Trade Commission (ITC) officially launching an investigation into the case.The US tra

K-bio's out-licensing this year reaches $9.3 bn

K-bio's out-licensing this year reaches $9.3 bn

As of Nov. 17, Korea's biotech and pharma overseas technology transfers for this year already exceed $9.3 billion. Overseas technology transfers from South Korean biotechs and pharmaceutical manufacturers this year have exceeded 11 trillion won ($9.3 billion), already hitting a fresh yearly hig

Daewoong Pharmaceutical aims to top $4 bn in sales by 2027

Daewoong Pharmaceutical aims to top $4 bn in sales by 2027

Daewoong Pharmaceutical CEO Jeon Seng-ho South Korea-based Daewoong Pharmaceutical Co. is hoping to achieve 5 trillion won ($4.4 billion) in sales by 2027, meaning that the company aims to grow fivefold in seven years given that it logged revenue of 1 trillion won in 2020. “The seeds
(* comment hide *}